Aldeyra Therapeutics, Inc.
NASDAQ:ALDXBiotechnology
+$0.06 today
- Market cap
- $54.28M
- Beta
- 1.19
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$0.45
Volume 1.45M
Average 2.13M
ALDX Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Aldeyra Therapeutics, Inc.NASDAQ: ALDX
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses declines year over year
Q1 FY2026 operating expenses of $3.48M fell 66.6% year over year, behind the -53.7% change in trailing-twelve-month operating expenses. Sequentially, it fell 47.8% from the prior quarter. Over 3 fiscal years it compounded at -17.4% a year.
Context
- Operating expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -66.6% toward the trailing-twelve-month pace of -53.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 35.27M USD
- Year-over-year change
- -41.3%
- 4-year CAGR
- -11.0%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 35.27M | -41.3% |
| FY2024 | 2024-12-31 | 60.12M | +40.5% |
| FY2023 | 2023-12-31 | 42.79M | -31.7% |
| FY2022 | 2022-12-31 | 62.68M | +11.5% |
| FY2021 | 2021-12-31 | 56.22M | — |
Operating Expenses vs competitors
How ALDX compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -53.7% is the 9th highest of 10, against a peer median of +7.3%.
- Over three fiscal years its annual growth of -17.4% compares with a peer median of +14.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $162.92M USD | +24.9% | +67.1% | — | |
| LTM Mar 2026 | $150.13M USD | -11.1% | -27.1% | 69.9% | |
| LTM Mar 2026 | $101.75M USD | +11.1% | -1.4% | 149.4% | |
| LTM Mar 2026 | $87.2M USD | — | +16.9% | 9463.1% | |
| LTM Mar 2026 | CHF 68.45M CHF | -14.4% | -1.1% | 1849.0% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $66.77M USD | +256.3% | +44.2% | — |
| LTM Mar 2026 | $56.42M USD | +67.9% | +11.5% | — | |
| LTM Mar 2026 | $37.72M USD | -21.8% | -10.5% | 7543.6% | |
GNLXGenelux Corporation | LTM Mar 2026 | $33.48M USD | +7.3% | +35.5% | 418487.5% |
| LTM Mar 2026 | $28.32M USD | -53.7% | -17.4% | — | |
| LTM Mar 2026 | -$55.19M USD | -179.1% | +31.6% | — | |
| Peer median (excluding ALDX) | — | +7.3% | +14.2% | 4696.3% | |
Competitors are the stored peer set for ALDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 44.94M | 47.31M | 29.46M | 48.22M | 25.66M |
| Selling, General & Admin | 11.28M | 15.37M | 13.34M | 11.89M | 9.6M |
| Operating Expenses | 56.22M | 62.68M | 42.79M | 60.12M | 35.27M |
| Depreciation & Amortization | 264.18K | 258.71K | 262.78K | 249.62K | 251.99K |
| EBITDA | (55.77M) | (60.07M) | (35.21M) | (53.68M) | (31.69M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (56.22M) | (62.68M) | (42.79M) | (60.12M) | (35.27M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 185.36K | 2.35M | 7.32M | 6.19M | 3.32M |
| Interest Expense | 1.74M | 1.69M | 2.07M | 1.93M | 1.91M |
| Other Income / Expenses | (1.56M) | 655.35K | 5.25M | 4.27M | 1.42M |
| Income Before Tax | (57.78M) | (62.02M) | (37.54M) | (55.85M) | (33.85M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (57.78M) | (62.02M) | (37.54M) | (55.85M) | (33.85M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.07) | (1.06) | (0.64) | (0.94) | (0.56) |
| EPS (Diluted) | (1.07) | (1.06) | (0.64) | (0.94) | (0.56) |
| Weighted Avg Shares | 54.04M | 58.41M | 58.94M | 59.48M | 60.06M |
| Weighted Avg Shares (Diluted) | 54.04M | 58.41M | 58.94M | 59.48M | 60.06M |
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
Intrinsic Alpha fair value
Locked
Current Price
$0.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.